2010
DOI: 10.1021/jm101031u
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and Biological Evaluation of 3-Biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as Novel Glycine Transporter 1 Inhibitors

Abstract: We describe the preparation and evaluation of a novel series of glycine transporter 1 (GlyT1) inhibitors derived from a high-throughput screening hit. The SAR studies resulted in the discovery of 3-biphenyl-4-yl-4-(2-fluorophenyl)-5-isopropyl-4H-1,2,4-triazole (6p). A pharmacokinetic study was also conducted and revealed that 6p had excellent oral bioavailability and ameliorated learning impairment in passive avoidance tasks in mice.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
16
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
6
2
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 42 publications
(16 citation statements)
references
References 18 publications
0
16
0
Order By: Relevance
“…Aryltriazole 30 showed very potent binding affinity (Ki = 0.0027 μmol/L) to CRF1 receptors with an IC50 of 0.049 μmol/L (Lowe et al, 2005). Several findings suggest that medications aimed at inhibiting the activity of glycine transporter 1 (GlyT1) may be useful as therapeutic agents for schizophrenia, dementia, and related disorders (Sugane et al, 2011). A series of 3biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles were evaluated as novel GlyT1 inhibitors and found that fluorophenylsubstituted triazole derivative 31 was the most potent one, which had improved GlyT1 inhibitory activity and selectivity against GlyT2.…”
Section: Anti-neuropathic Activity Of Triazole Derivativesmentioning
confidence: 99%
“…Aryltriazole 30 showed very potent binding affinity (Ki = 0.0027 μmol/L) to CRF1 receptors with an IC50 of 0.049 μmol/L (Lowe et al, 2005). Several findings suggest that medications aimed at inhibiting the activity of glycine transporter 1 (GlyT1) may be useful as therapeutic agents for schizophrenia, dementia, and related disorders (Sugane et al, 2011). A series of 3biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles were evaluated as novel GlyT1 inhibitors and found that fluorophenylsubstituted triazole derivative 31 was the most potent one, which had improved GlyT1 inhibitory activity and selectivity against GlyT2.…”
Section: Anti-neuropathic Activity Of Triazole Derivativesmentioning
confidence: 99%
“…An HTS hit (Figure 11.9, A) from a GlyT1 screen was found to be a low micromolar inhibitor of GlyT1 but displayed no selectivity over the closely related GlyT2 [51]. It was noted that increasing the steric bulk at either the 3-or 4-position on the triazole ring increased the selectivity for GlyT1.…”
Section: Glycine Transporter 1 (Glyt1) Inhibitorsmentioning
confidence: 99%
“…Oxadiazoles, including 1,2,4-oxadiazoles and 1,3,4-oxadiazoles which possess various bioactivities like antibacterial, antifungal and antitumor potencies [178], have relatively high reactivity due to the inductive effect of oxygen atom in the oxadiazole ring, and they have been investigated very well to transform into more stable heterocycles, especially 1,2,4-triazole derivatives [179][180][181][182][183][184][185][186][187]. In recent years, the prepared triazoles via rearrangement of oxadiazoles usually exhibited wide applications in medicinal chemistry especially as antitubercular [188] and antiproliferative agents [189], and also in supramolecular chemistry as progesterone receptors and ligands of coordination polymers [64,190,191].…”
Section: Transformations Of Five-membered Heterocyclic Compoundsmentioning
confidence: 99%